" class="no-js "lang="en-US"> Jan Thirkettle - Medtech Alert
Friday, March 29, 2024
Jan Thirkettle

Jan Thirkettle

About Jan Thirkettle

Jan has more than 20 years’ experience of building and leading cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of multiple therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer during a 5 year period from company start up through to successful IPO, overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple roles spanning from Discovery to Manufacturing environments, including senior leadership roles in the rapidly growing Biopharma business. Latterly, Jan oversaw the establishment of the Cell & Gene Therapy platform unit and played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field.  Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.

Related Story

Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development

May 31 2022

Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on […]

Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO

July 5 2021

Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its […]